Pacira BioSciences (PCRX) Expected to Announce Quarterly Earnings on Tuesday

Pacira BioSciences (NASDAQ:PCRX) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Pacira BioSciences to post earnings of $0.61 per share and revenue of $176.35 million for the quarter.

Pacira BioSciences Stock Up 5.5 %

Shares of PCRX opened at $27.14 on Tuesday. The company’s 50-day simple moving average is $24.52 and its 200-day simple moving average is $21.61. The stock has a market capitalization of $1.26 billion, a PE ratio of -13.37 and a beta of 0.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences has a 1 year low of $11.16 and a 1 year high of $31.67.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, April 8th. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and increased their price objective for the company from $8.00 to $25.00 in a report on Thursday, January 30th. HC Wainwright raised their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a report on Tuesday, April 8th. Finally, Barclays lifted their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $26.67.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.